Full Press Release Details
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase.
IDYA
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
Key Takeaway: IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
Price reaction · baseline $15.99 (2023-03-13 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
-0.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma